Saskatchewan to cover two new ovarian cancer drugs Dec. 1

By Saskatchewan Herald ·

A nurse's hands support a patient's arm during an intravenous chemotherapy infusion (file photo).
Linda Bartlett, National Cancer Institute / Wikimedia Commons (Public domain)

Saskatchewan will cover two drugs for eligible ovarian cancer patients starting December 1, 2026, the provincial government announced Tuesday.

The drugs are Elahere and Keytruda. Coverage applies to patients whose disease no longer responds to standard therapy, with chemotherapy as the example, the release says.

The government says clinical studies found both drugs helped patients live longer and delay progression of the disease. The release gives no figures. The government expects about eight to 10 Saskatchewan patients a year to benefit from access to both.

Health Minister Jeremy Cockrill said the treatments will give patients and families hope and ensure access to high-quality cancer care close to home.

Denise Budz, vice-president of care services at the Saskatchewan Cancer Agency, said the coverage gives women access to the latest evidence-based therapies. The release says the decision follows national reviews of the drugs’ safety, effectiveness and value, and pricing talks through the pan-Canadian Pharmaceutical Alliance.

Tania Vrionis, CEO of Ovarian Cancer Canada, said her organization is proud to see Saskatchewan make the drugs accessible. She called the move a milestone for patients and families who had been waiting.

The release says the Saskatchewan Cancer Agency received a 2026-27 budget of $308.6 million. The budget supports prevention, detection, diagnosis, treatment, research and patient support.

The province encourages patients who think they may be eligible to speak with their oncologist.